# Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor

Source: https://onco.cc/trials/nct00889525/  
OnCo record `nct00889525` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Cabergoline in Pituitary tumours, run by Seth Gordhandas Sunderdas Medical College, completed.

## Summary

Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor is a phase 3 interventional study registered as NCT00889525 by Seth Gordhandas Sunderdas Medical College, started 2007-11. Interventions recorded: Cabergoline. Conditions recorded: Cushing's Disease, Corticotroph Adenoma.

Linked to the drug Cabergoline because the registry names it among its interventions and Pituitary tumours among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT00889525
- Phase: 3
- Setting: Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor
- Sponsor: Seth Gordhandas Sunderdas Medical College

## Sources

- ClinicalTrials.gov NCT00889525: https://clinicaltrials.gov/study/NCT00889525

## Connected records

- cancers: [Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma](https://onco.cc/cancers/pituitary-tumours/)
- drugs: [Cabergoline](https://onco.cc/drugs/cabergoline/)

---
JSON: https://onco.cc/api/v1/entities/nct00889525.json